Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Post by Jesus4Prezon Sep 26, 2020 9:38pm

431 Views

Post# 31626037

Discussions Involve Multiple Partners in Varying Formats

DM said "We have multiple partners we are discussing in multiple different formats." Could this be a hint toward a full buyout, not just a 'partnership'?

"The development of this company is 'straight up from here'." Could this be insinuation that the share price will spike?

J4P

Bullboard Posts

BMO evolves InvestorLine with enhanced tools for options trading